CClinicalTrials.gg
Not yet recruitingNCT07796932MNEMOBUpdated Sep 1, 2026

Characterisation of MNEsic Involvement in Patients With Obesity.

An observational study in Obesity (Disorder), sponsored by University Hospital, Bordeaux. Not yet recruiting. Open to participants aged 30 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by University Hospital, Bordeaux · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
150
Ages
30 Years to 50 Years
Sex
All
01

Study summary

The aim of the study is therefore to characterise memory impairment in a middle-aged population with obesity and to clarify the role of inflammation in obesity-related memory impairment.

The hypothesise that, as in an elderly population, neurological and memory impairment in a population of middle-aged obese individuals is heterogeneous, with varying levels of memory impairment characterised by neuropsychological test results. This heterogeneity in neuropsychological tests may be linked to markers of inflammation and brain imaging biomarkers identified previously in the litterature.

02

Conditions studied

  • Obesity (Disorder)

Browse trials for

Keywords

  • neurological inflammation
  • Obesity
  • CANTAB
03

Who can participate

Ages eligible
30 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Recruitment will take place within the Specialised Obesity Centre at Bordeaux University Hospital.

As part of their obesity treatment within the department, new patients first attend a consultation, after which they are usually admitted for a five-day educational programme to undergo a comprehensive initial multidisciplinary assessment (covering medical, dietary, psychological, physical activity and social aspects).

Inclusion criteria

  • Patients suffering from obesity with a BMI between 30 and 45 kg/m²
  • Patients aged between 30 and 50 receiving educational care during the week at the CSO (Endocrinology, Diabetology and Nutrition Department) of the Bordeaux University Hospital.
  • Right-handed patients
  • Persons affiliated with or beneficiaries of a social security scheme.
  • Free, informed and express consent

Exclusion criteria

Exclusion Criteria:

  • Patients currently undergoing treatment with neuroleptics or who have stopped treatment within the last 3 months.
  • Pregnant or breastfeeding patients
  • Known current or past neurological disease
  • Proven depressive syndrome treated
  • Patients with type 1 or type 2 diabetes
  • Uncontrolled dysthyroidism
  • MMS\< 25
  • Patients with proven genetic obesity
  • Contraindication to MRI
  • Chronic use of NSAIDs or corticosteroids
  • Loss of 5% of body weight in the 3 months prior to the study
  • Acute infection
  • Persons deprived of their liberty by judicial or administrative decision
  • Adults subject to legal protection measures (guardianship, curatorship, judicial protection)
04

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • Magnetic Resonance Imaging, CANTAB questionnaires

    Other: RMI and Questionnaires

Interventions

  • OtherRMI and Questionnaires

    Magnetic resonance imaging (MRI) will collect anatomical information (3D T1 weighted images) to compute the volumes of the hypothalamus, hippocampus and the other brain parcels. Executive functions using the CANTAB tests and validated questionnaires will be performed.

05

What researchers measure

Primary outcomes

  1. Memory function characteristic

    The main objective is to characterise memory function in a population of middle-aged individuals suffering from obesity using the CANTAB Paired Associates Learning (PAL) test.

    Time frame: 37 months after inclusion day

06

Study locations

No study locations are listed for this record.

07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07796932
Lead sponsor
University Hospital, Bordeaux
Responsible party
Sponsor
First posted
Sep 1, 2026
Start date
Jan 2027 (estimated)
Primary completion
Feb 2030 (estimated)
Completion
Feb 2030 (estimated)
Last update
Sep 1, 2026

Study contacts

Blandine GATTA-CHERIFI, Pr
Contact
blandine.gatta-cherifi@chu-bordeaux.fr
05 24 54 93 41 ext. +33
Daniela COTA, Pr
study director · INSERM u1215

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion